ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Clinical practice guidelines"

  • Abstract Number: 062 • 2023 Pediatric Rheumatology Symposium

    Assessment of Barriers and Facilitators in Implementation of the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans

    Cagri Yildirim-Toruner1, Daniel Glaser2, Timothy Beukelman3, Stacy Ardoin4, Ahmar Hashmi5, Rajdeep Pooni6, Maria Fernandez5, Vincent Del Gaizo7, Leslie Hanrahan7, Mary Ellen Riordan8, Stacey Tarvin9 and CARRA Registry Investigators7, 1Baylor College of Medicine, Texas Children's Hospital, Houston, TX, 2Yale University School of Medicine, New Haven, CT, 3University of Alabama at Birmingham, Birmingham, AL, 4Nationwide Children's Hospital, Columbus, OH, 5The University of Texas Health Sciences Center at Houston, Institute for Implementation Science, Houston, TX, 6Stanford University, Palo Alto, CA, 7CARRA, Washington, DC, 8Hackensack Meridian Health/ Joseph M. Sanzari Children's Hospital, Hackensack, NJ, 9Riley Hospital for Children at Indiana University Health, Indianapolis, IN

    Background/Purpose: Since 2010, the Childhood Arthritis and Rheumatology Research Alliance (CARRA) has developed 12 consensus treatment plans (CTP) with the aim of reducing treatment variability…
  • Abstract Number: L17 • ACR Convergence 2022

    Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis

    Robert Maughan1, Andrew Porter1, Chanaka Dahanayake2, Claudia Ianonne1, Ritu Alapat1, Charis Pericleous1, Taryn Youngstein3 and Justin Mason1, 1Imperial College London, London, United Kingdom, 2Barts Health NHS Trust, London, United Kingdom, 3Imperial NHS Trust, London, United Kingdom

    Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…
  • Abstract Number: 1279 • ACR Convergence 2022

    Development of ACR Longitudinal Digital Quality Measures for Systemic Lupus Erythematosus: A Literature Review and Modified Delphi Consensus Study

    Christie Bartels1, April Jorge2, Candace Feldman3, Claire Barber4, April Barnado5, Bonnie Bermas6, Ali Duarte-Garcia7, Shivani Garg8, Leah Haseley9, Shraddha Jatwani10, Tracy Johansson11, Alex Limanni12, Wendy Rodgers13, Brad Rovin14, Yesenia Santiago-Casas15, Lisa Suter16, Jennifer Ude11, JoAnn Zell17 and Jinoos Yazdany18, 1University of Wisconsin School of Medicine and Public Health, Madison, WI, 2Massachusetts General Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA, 4University of Calgary, Calgary, AB, Canada, 5Vanderbilt University Medical Center, Nashville, TN, 6UT Southwestern, Dallas, TX, 7Mayo Clinic, Rochester, MN, 8University of Madison, School of Medicine and Public Health, Madison, WI, 9University of Washington, Harborview Medical Center, Seattle, WA, 10Albert Einstein Medical Center, Ambler, PA, 11American College of Rheumatology, Atlanta, GA, 12Self, Dallas, TX, 13Lupus Foundation of America, Torrance, CA, 14The Ohio State University, Columbus, OH, 15Integral Rheumatology and Immunology Specialists, Plantation, FL, 16Yale School of Medicine, New Haven, CT, 17University of Colorado Anschutz Medical Campus, Denver, CO, 18UCSF, San Francisco, CA

    Background/Purpose: Significant morbidity and mortality urge efforts to improve quality of care for people with systemic lupus erythematosus (SLE). Yet, none of the 25 American…
  • Abstract Number: 1284 • ACR Convergence 2022

    Comparative Effectiveness Randomized Controlled Trials in Rheumatology Guidelines

    Kathryn Henry1, Desh Nepal2, Erin Valley2, Connor Pedersen2, Ali Duarte-Garcia3 and Mike Putman4, 1Medical College of Wisconsin, Manitowoc, WI, 2Medical College of Wisconsin, Milwaukee, WI, 3Mayo Clinic, Rochester, MN, 4The Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Comparative effectiveness randomized controlled trials (RCTs) compare two active interventions in a head-to-head design. They are useful for informing clinical practice guidelines, but the…
  • Abstract Number: 1671 • ACR Convergence 2022

    Current Cervical Cancer Screening Guidelines Are Unsatisfactory for the Needs of Systemic Lupus Erythematosus Patients

    Zehra Kazmi1, Carlos Lorenzo1, Farwa Kazmi2 and Agustin Escalante3, 1University of Texas Health Sciences Center San Antonio, San antonio, TX, 2Gulf Medical University, Ajman, United Arab Emirates, 3University of Texas Health Science Center at San Antonio, San Antonio, TX

    Background/Purpose: HPV infection is a risk factor for cervical cancer. SLE patients have increased rates of HPV infection, cervical dysplasia and cancer. Present guidelines for…
  • Abstract Number: 1765 • ACR Convergence 2022

    Safety of the Recombinant Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with JAKi Drugs

    Ana Pons1, José Rosas1, José Miguel Senabre2, JC Cortés-Quiroz1, Carmen Raya-Santos2, Gregorio Santos-Soler2, Lara Pons2, Marisa Lorente2, José Antonio Bernal3, Xavier Barber4 and José Alberto Garciía-Gómez4, 1Rheumatology Department, Hospital Marina Baixa, Villajoyosa, Spain, 2Hospital Marina Baixa, Villajoyosa, Spain, 3Hospital Marina Baixa (Villajoyosa), Alicante, Spain, 4CIO Miguel Hernández University Elche, Alicante, Spain

    Background/Purpose: Patients receiving treatment with JAK inhibitor drugs (JAKi) have an increased risk of developing herpes zoster (HZ). A new recombinant vaccine effective against HZ…
  • Abstract Number: 0121 • ACR Convergence 2022

    Rheumatoid Arthritis Care Experiences of Black People Living in Canada: A Qualitative Study to Inform Treatment Guidelines

    Megan Thomas1, Cheryl Barnabe2, Tessa Kleissen2, Diane Lacaille3, Glen Hazlewood2, Nejat Hassen4, Richard Henry5, Kelly English6, Michael Kuluva7, Aurore Fifi-Mah2 and Nicole Johnson2, 1University of British Columbia, Vancouver, BC, Canada, 2University of Calgary, Calgary, AB, Canada, 3Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 4University of British Columbia, Arthritis Research Canada, RICHMOND, BC, Canada, 5McGill University, Montréal, QC, Canada, 6Arthritis Patient Advisory Board of Arthritis Research Canada, Vancouver, BC, Canada, 7Creaky Joints, Vancouver, BC, Canada

    Background/Purpose: Guidelines may unintentionally introduce inequities in care through recommendations that do not reflect the realities of healthcare access and quality for persons who are…
  • Abstract Number: 0357 • ACR Convergence 2022

    Voclosporin Is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

    Hans-Joachim Anders1, Raymond Federico2, Vanessa Birardi3 and Henry Leher3, 1University of Munich, Munich, Germany, 2Aurinia Pharmaceuticals, Inc., Victoria, BC, Canada, 3Aurinia Pharmaceuticals Inc, Rockville, MD

    Background/Purpose: Pooled data from the Phase 2 AURA-LV and Phase 3 AURORA 1 studies demonstrated that adding voclosporin, a novel calcineurin inhibitor, to mycophenolate mofetil…
  • Abstract Number: 0200 • ACR Convergence 2021

    In Undifferentiated Arthritis, DMARD-treatment Intensified During the Last Decennia but Did Not Result in Improved Outcomes

    Marloes Verstappen, Xanthe Matthijssen and Annette H.M van der Helm-van Mil, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: International guidelines stress timely DMARD-initiation in early arthritis, also when classification-criteria are not yet fulfilled. Consequently, undifferentiated arthritis (UA)-patients are increasingly treated despite placebo-controlled…
  • Abstract Number: 0517 • ACR Convergence 2021

    TPMT and NUDT15 Genotype and Azathioprine Myelotoxicity in Patients with Inflammatory Conditions: Results from Real-World Clinical Practice

    Alyson Dickson1, Laura Daniel2, Jacy Zanussi1, Wei-Qi Wei1, Dale Plummer1, William Dupont3, Ge Liu1, Prathima Anandi1, Tyler Reese4, Kelly Birdwell1, Vivian Kawai5, Adriana Hung1, Qiping Feng1, Nancy J. Cox1, C. Michael Stein1 and Cecilia Chung1, 1Vanderbilt University Medical Center, Nashville, TN, 2Vanderbilt University Medical Center, Pegram, TN, 3Vanderbilt University, Nashville, TN, 4Vanderbilt University Medical Center, Madison, TN, 5Vanderbilt Universty Medical Center, Nashville, TN

    Background/Purpose: Azathioprine is frequently used for the treatment of several inflammatory conditions. However, treatment is often limited by adverse events, in particular myelotoxicity. Both thiopurine-S-methyltransferase…
  • Abstract Number: 0606 • ACR Convergence 2021

    How Might We Care for Rheumatoid Arthritis (RA) Patients Unable to See a Rheumatologist And/or Use Certain of Our Medications? Proposed Preliminary Recommendations for RA Patients Who Don’t Meet Our Established Guidelines

    Nicole Zagelbaum Ward1, Abhimanyu Amarnani1, Baljeet Rai2, Corinne Feldman1, Brett Feldman1 and Richard Panush1, 1LAC+USC Medical Center, Los Angeles, CA, 2LAC USC, Los Angeles, CA

    Background/Purpose: Physicians share responsibilities to promote social justice and assure equitable healthcare for all. Street medicine (SM) is a field dedicated to address the need…
  • Abstract Number: 0648 • ACR Convergence 2021

    Improving Post-Rituximab Hypogammaglobulinemia Risk Assessments: A Fellows’ Quality Improvement Initiative

    Beth Rutstein1, Melissa Argraves2, Atiye Bilgic Dagci2, Sarah Bayefsky2, Julia Rood2, Julie Chase3, Jay Mehta2, Melissa Lerman2, Cory Stingl4 and Jon Burnham2, 1Children's Hospital of Philadelphia, Wynnewood, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3The Children's Hospital of Philadelphia, Philadelphia, PA, 4Children's Hospital of Philadelphia, Durham, NC

    Background/Purpose: Hypogammaglobulinemia following rituximab therapy is a potentially severe complication that can lead to infection-related morbidity and mortality. If recognized, clinicians may prevent infections by…
  • Abstract Number: 0653 • ACR Convergence 2021

    Adherence to the 2015 ACR Guidelines for the Management of Polymyalgia Rheumatica and Screening for Osteoporosis at a Tertiary Care Medical Center

    Padmini Parameswaran1 and Michael Lucke2, 1Allegheny Health Network Medical Education Consortium, Pittsburgh, PA, 2Allegheny Health Network, Pittsburgh, PA

    Background/Purpose: Since the first description of polymyalgia rheumatica (PMR) in the early 1950s, the ideal dose and duration of glucocorticoid therapy has varied. In 2015,…
  • Abstract Number: 0658 • ACR Convergence 2021

    ACCORD: A Novel Rheumatology Transition Clinic Structure for Adolescent and Young Adult Patients with Childhood Onset Rheumatic Disease

    Rebecca Overbury1, Kelly Huynh2, Tracy Frech1, John Bohnsack1 and Aimee Hersh1, 1University of Utah, Salt Lake City, UT, 2Intermountain Health Care, Salt Lake City, UT

    Background/Purpose: The transition of health care from Pediatric to Adult providers for adolescents and young adults with childhood onset rheumatic disease continues to be associated…
  • Abstract Number: 0960 • ACR Convergence 2021

    The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: 24-Month Outcomes

    Yukiko Kimura1, Sarah Ringold2, George Tomlinson3, Laura Schanberg4, Anne Dennos5, Mary Ellen Riordan6, Vincent Del Gaizo7, Katherine Murphy8, Pamela Weiss9, Brian Feldman10, Marc Natter11 and The STOP-JIA CARRA Registry Investigators12, 1Hackensack University Medical Center, New York, NY, 2Seattle Children's Hospital, Seattle, WA, 3University of Toronto, Toronto, ON, Canada, 4Duke University Medical Center, Durham, NC, 5Duke University, Durham, NC, 6Hackensack University Medical Center, Westwood, NJ, 7Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, 8Childhood Arthritis & Rheumatology Research Alliance (CARRA), New Orleans, LA, 9Children's Hospital of Philadelphia, Philadelphia, PA, 10The Hospital for Sick Children, Toronto, ON, Canada, 11Boston Children's Hospital, Boston, MA, 12Childhood Arthritis & Rheumatology Research Alliance (CARRA), Milwaukee, WS

    Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinical inactive disease (CID) in untreated polyarticular JIA…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences